biotech

automatic inspection machine

Top Biopharma Movers of the Past Week

A few biopharma companies made massive runs this past week. The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the ...
Read Full Story »
Female patient on gurney

Is This the Turnaround Cempra Has Been Looking For?

Shares of Cempra Inc. (NASDAQ: CEMP) saw an incredible gain on Friday after the company announced the results from its late-stage trial for the treatment of patients with acute bacterial ...
Read Full Story »
automatic inspection machine

Large Cap Biotech Stocks to Buy May Be the Cheapest in Years

Almost every asset class is overbought now, and the few that aren’t — with the exception of one — have good reasons. Utilities and other income proxy stocks that were big in ...
Read Full Story »
child with cancer

With New Cash and Cancer Targets, Analyst Sees Almost 200% Upside in Sierra Oncology

Sierra Oncology Inc. (NASDAQ: SRRA) is far from a household name for investors who delve into health care, pharmaceuticals and biotech. In fact, Sierra would have to be considered quite ...
Read Full Story »
research

Tuesday’s Top Biopharma Movers

A few biopharma companies made massive runs on Tuesday morning. The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the ...
Read Full Story »
Prescription drugs

How Alexion’s Pipeline Is Driving Earnings

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) released its most recent earnings report before the markets opened on Thursday. This company posted $1.26 in earnings per share (EPS) on $831 million in ...
Read Full Story »
automatic inspection machine

How Gene Editing Just Got Rocked by Major Patent Ruling

The possibilities around gene editing are almost endless. Some of the goals and hopes around gene editing sound like they were pulled right out of a science fiction or futuristic ...
Read Full Story »
Woman sitting alone and depressed, sad, miserable

Can Sage Therapeutics Press Even Further With Its Depression Trial?

Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) saw a handy gain on Monday after the company announced a successful mid-stage trial for the treatment of major depressive disorder (MDD). Specifically the ...
Read Full Story »
Medical vaccine in shoulder, vaccination

What Analysts Are Prescribing Gilead After Earnings

Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter earnings after markets closed on Tuesday. The stock hit a new multiyear low on Wednesday and pushed even lower on Thursday to a price ...
Read Full Story »
Wow

Major Biotechs Scare Off Loads of Short Sellers

The short interest data are out for the most recent settlement date, January 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »
Jon's friends

Is This the Big Turnaround Acorda Needs?

Shares of Acorda Therapeutics Inc. (NASDAQ: ACOR) saw a handy gain in early trading on Thursday after the company reported results from its late-stage Parkinson’s trial. Basically, the company announced Phase ...
Read Full Story »
thumbs up and down

What Analysts Are Saying About Gilead Sciences After Earnings

After Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter earnings after markets closed on Tuesday, the stock hit a new multiyear low, not seen since 2014. Across the board analysts saw ...
Read Full Story »
Prescription Drugs, Pills

Wednesday’s Biggest Biopharma Movers

Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made splash, while one giant company posted a massive loss. Although ...
Read Full Story »
burning cash

Why Gilead Earnings Were Not Up to Snuff

Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter earnings after markets closed on Tuesday. The company posted $2.70 in earnings per share (EPS) and $7.3 billion in revenue, compared with the ...
Read Full Story »
Medical vaccine in shoulder, vaccination

What to Expect From Gilead Earnings

Gilead Sciences Inc. (NASDAQ: GILD) is set to report its fourth-quarter financial results after the markets close on Tuesday. The consensus estimates call for $2.61 in earnings per share (EPS) ...
Read Full Story »